Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Qingmin Ruan

Addiction Psychiatry Houston, TX Medical Doctor

NPI 1548586308 CMS profile 2500218

1504 Taub Loop, Houston, TX 77030

Open in the dashboard

General payments

$510

20 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Qingmin Ruan of Houston, TX is reported in the CMS Open Payments database as having received $510 across 20 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Addiction Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $45 1
2024 General $92 1
2020 General $106 5
2019 General $267 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Qingmin Ruan
  • Addiction Psychiatry median
  • Middle half of Addiction Psychiatry
  • National median

In program year 2025, general payments to Qingmin Ruan were reported at $45. Among 180 Addiction Psychiatry profiles paid that year, the median was $138 and the middle half received between $45 and $421.

Show as a table
Year Qingmin Ruan Addiction Psychiatry median Middle half National median
2019 $267 $142 $56–$476 $163
2020 $106 $78 $21–$210 $114
2021 $0 $112 $35–$458 $132
2022 $0 $113 $39–$343 $149
2023 $0 $134 $47–$429 $160
2024 $92 $129 $42–$349 $164
2025 $45 $138 $45–$421 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $273 12 payments
  2. BIOTRONIK NRO, Inc. $137 2 payments
  3. Teva Pharmaceuticals USA, Inc. $58 3 payments
  4. Indivior Inc. $25 2 payments
  5. Otsuka America Pharmaceutical, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $510 20 payments
Products named General payments · program years 2019–2025
  1. INVEGA SUSTENNA $273 12 payments
  2. INVEGA TRINZA $248 11 payments
  3. SPRAVATO $203 9 payments
  4. Prospera Not Applicable $92 1 payment
  5. AUSTEDO $58 3 payments
  6. Prospera Not Applicable $45 1 payment
  7. PERSERIS $25 2 payments
  8. ABILIFY MAINTENA $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,470

Median for Psychiatry: 574

Drug cost

$371,461

Median for Psychiatry: $27,624

Branded share of claims

19%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 89 $255,741
Aristada Aripiprazole Lauroxil Brand 13 $39,704
Risperdal Consta Risperidone Microspheres Brand 18 $20,789
Trintellix Vortioxetine Hydrobromide Brand 17 $11,441
Aripiprazole Generic 67 $8,534
Olanzapine Generic 105 $6,125
Lurasidone Hcl Generic 26 $4,258
Divalproex Sodium Er Divalproex Sodium Brand 43 $3,127
Benztropine Mesylate Generic 129 $2,982
Clozapine Generic 23 $2,557

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$4,625

Medicare's payments for the services billed

Medicare patients

41

Average age 54

Services billed

140

19 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Depression 39%
Diabetes 32%
Arthritis 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

20 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Addiction Psychiatry in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record